AbbVie completes $8.0 billion senior notes offering in seven series
On March 4, 2026, AbbVie completed an underwritten public offering of seven series of senior notes, totaling $8.0 billion in principal, maturing between 2028 and 2066. The notes are unsecured and rank equally with AbbVie's existing unsecured debt, so the offering adds to the company's long-term borrowing obligations that shareholders' interests sit behind.
Key points
- Seven series issued: $750 million floating rate notes and $1.5 billion 3.775% notes due 2028 among the fixed-rate series, plus notes due 2031, 2033, 2036, 2056 and 2066 with coupons from 4.125% to 5.650%
- Floating rate and 2028 notes mature March 3, 2028; the other series mature March 15 of their respective years
- Notes governed by a Supplemental Indenture No. 12 dated March 4, 2026, with U.S. Bank Trust Company, National Association as trustee
- Offering registered under a Form S-3ASR dated February 14, 2025; prospectus supplement dated February 24, 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.